Tislelizumab vs Toripalimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Tislelizumab
Marketed by BeOne Medicines and partners
NCT03358875 · Phase 3 · completed
The 805-participant trial was randomized and actively controlled with docetaxel, and its co-primary clinical endpoint of overall survival was met in both the full population and the PD-L1-positive subgroup. However, treatment assignment was not blinded, so despite the large sample and statistically significant survival results, the evidence is rated moderate rather than strong.
Next expected readout: November 2026 · NCT06704620 (registry estimate)
No aligned efficacy figure on record for this race.
Toripalimab
Marketed by Coherus BioSciences, Inc. and partners
NCT03856411 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled trial of 465 patients met its primary endpoint: median progression-free survival was 8.4 months with toripalimab plus chemotherapy versus 5.6 months with placebo plus chemotherapy, a highly statistically significant improvement.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT06426511 (registry estimate)
Reported efficacy
MPR rate in stage III population evaluated by BIPR (up to 7 weeks after neoadjuvant); EFS in stage III population evaluated by investigators (up to 3 years); MPR rate in stage II-III population evaluated by BIPR (up to 7 weeks after neoadjuvant); EFS in stage II-III population evaluated by investigators (up to 3 years): Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met. (met)
Result source: NCT04158440
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Tislelizumab | Toripalimab |
|---|---|---|
| PFS, median | 7.6 vs 5.5vs Paclitaxel + CarboplatinNCT035947475 other results
| 8.4 vs 5.6a+2.8 vs placeboNCT03856411 |
| OS, median | 26.1 vs 19.4vs Paclitaxel + CarboplatinNCT035947471 other result
| —Not posted · NCT03856411 |
| ORR | 74.2% vs 47.9%vs Paclitaxel + CarboplatinNCT035947473 other results
| —Not posted · NCT03856411 |
| Duration of response, median | 8.4 vs 4.3vs Paclitaxel + CarboplatinNCT035947473 other results
| —Not posted · NCT03856411 |
PFS, median
- Tislelizumab
- 7.6 vs 5.5vs Paclitaxel + CarboplatinNCT03594747
5 other results
- 7.6 vs 5.5 NCT03594747
- 7.7 vs 5.5 NCT03594747
- 9.6 vs 5.5 NCT03594747
- 9.6 vs 5.5 NCT03594747
- 9.8 vs 5.5 NCT03594747
- Toripalimab
- 8.4 vs 5.6a+2.8 vs placeboNCT03856411
OS, median
- Tislelizumab
- 26.1 vs 19.4vs Paclitaxel + CarboplatinNCT03594747
1 other result
- 23.3 vs 19.4 NCT03594747
- Toripalimab
- —Not posted · NCT03856411
ORR
- Tislelizumab
- 74.2% vs 47.9%vs Paclitaxel + CarboplatinNCT03594747
3 other results
- 73.9% vs 47.9% NCT03594747
- 70% vs 49.6% NCT03594747
- 78.2% vs 49.6% NCT03594747
- Toripalimab
- —Not posted · NCT03856411
Duration of response, median
- Tislelizumab
- 8.4 vs 4.3vs Paclitaxel + CarboplatinNCT03594747
3 other results
- 8.6 vs 4.3 NCT03594747
- 10.6 vs 4.8 NCT03594747
- 8.8 vs 4.8 NCT03594747
- Toripalimab
- —Not posted · NCT03856411
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Tislelizumab: 2 of 4 rows · Toripalimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tislelizumab | Toripalimab |
|---|---|---|
| Dropout rate | n/a: no completion milestoneTislelizumab + Nab-paclitaxel + Caa NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more resultn/a: no completion milestoneTislelizumab + Paclitaxel + Carbop NCT03594747 · Phase 3 · registry result, not featured evidence · combination | — |
| Discontinued due to AEs | —Tislelizumab + Nab-paclitaxel + Caa NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more result—Tislelizumab + Paclitaxel + Carbop NCT03594747 · Phase 3 · registry result, not featured evidence · combination | — |
| Serious AEs | 46.6%Tislelizumab + Nab-paclitaxel + Caa NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more result46.7%Tislelizumab + Paclitaxel + Carbop NCT03594747 · Phase 3 · registry result, not featured evidence · combination | — |
| Most frequent reported AEs | a anaemia 94.1% alopecia 69.5% neutrophil count decreased 61.9% NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more resultanaemia 89.2% alopecia 65% neutrophil count decreased 65% NCT03594747 · Phase 3 · registry result, not featured evidence · combination | — |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tislelizumab
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Nasopharyngeal Carcinoma
Shared mechanism: PD-1 · full Nasopharyngeal Carcinoma pipeline
Tislelizumab
Marketed by BeOne Medicines and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06177301 (registry estimate)
No aligned efficacy figure on record for this race.
Toripalimab
Marketed by Coherus BioSciences, Inc. and partners
NCT03581786 · Phase 3 · completed
JUPITER-02 was a randomized, double-blind, placebo-controlled Phase 3 in 289 patients with recurrent or metastatic nasopharyngeal carcinoma. Its primary endpoint, independently reviewed progression-free survival, is a clinical outcome and was met (HR 0.52). Figures are from the FDA label; the sources read give no power calculation, so the grade is moderate.
Next expected readout: December 2026 · NCT06323239 (registry estimate)
Reported efficacy
IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1 (up to 2 years): Primary endpoint, IRC-assessed PFS: median 11.7 vs 8.0 months, hazard ratio 0.52 (95% CI 0.36 to 0.74), toripalimab plus gemcitabine-cisplatin vs placebo plus gemcitabine-cisplatin (LOQTORZI label, JUPITER-02). (met)
Result source: NCT03581786
Results for Nasopharyngeal Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Tislelizumab: registry results are on file for Nasopharyngeal Carcinoma, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tislelizumab's landscape · Toripalimab's landscape